...
Topic | Discussed? | Notes |
---|---|---|
Upcoming OOO | Yes |
|
Previous Action Items |
|
|
Specimen CMT - review of terms with questions |
| |
CALL ADJOURNED | Yes | 1:?? PM ET |
Specimen CMT pilot implementers | No |
|
Specimen CMT - Hosting Options | No |
|
Specimen CMT - education | No |
|
Specimen CMT - tracking implementation impact
| No |
|
Specimen CMT - Compare to NHS Medical Terminology testing | No |
|
LOINC to SNOMED CT mapping | No |
|
Reporting Biomarkers to Cancer registries | No | National Program of Cancer Registries (NPCR) | CDC Sandy Jones will put together a one-pager - Nancy will reach out |
Future projects for this call after CMT | No |
|
Recording:
From Chat:
John Snyder (NLM): https://www.isbt128.org/technical-documents
John Snyder (NLM): Scott A. Brubaker (he/him/his)
John Snyder (NLM): Scott A. Brubaker (he/him/his) Director, Division of Human Tissues Office of Cellular Therapy and Human Tissue CMC Office of Therapeutic Products FDA | Center for Biologics Evaluation and Research10903 New Hampshire Avenue | Silver Spring, MD 20993scott.brubaker@fda.hhs.gov
Action items
Quick decisions not requiring context or tracking
...